Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

EMA Updates Pradaxa Bleeding Guidance

Filed May 25th, 2012 Laurie

The European Medicines Agency says doctors and patients should be given clearer guidance on how to avoid major bleeding events while using the blood-thinning drug Pradaxa, which is a major money maker for Boehringer Ingelheim.

The agency says data still shows a positive risk-benefit balance of the drug, even in the face of reports of fatal bleeding cases.

Pradaxa was originally touted as a “miracle drug” of sorts, replacing the longtime standard Coumadin, which is harder to regulate, and has a lengthy laundry list of drug interactions and side effects. It is prescribed to patients with atrial fibrillation after hip and knee surgery to prevent strokes. Atrial fibrillation is a common disorder among the elderly population.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!